Cargando…

Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy

OBJECTIVE: The aims of this study were to examine the symptom severity and interference among patients with lung cancer treated with PD-1 immunotherapy, explore whether those symptoms were clustered together, and identify factors associated with symptom clusters. METHODS: A cross-sectional study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guolong, Weng, Huiwen, Li, Yinghong, Li, Pingdong, Gong, Yucui, Chen, Jieya, Wei, Lin, Zeng, Linghui, Zeng, Yingchun, Cheng, Andy SK.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345784/
https://www.ncbi.nlm.nih.gov/pubmed/35935261
http://dx.doi.org/10.1016/j.apjon.2022.100103
_version_ 1784761507889807360
author Zhang, Guolong
Weng, Huiwen
Li, Yinghong
Li, Pingdong
Gong, Yucui
Chen, Jieya
Wei, Lin
Zeng, Linghui
Zeng, Yingchun
Cheng, Andy SK.
author_facet Zhang, Guolong
Weng, Huiwen
Li, Yinghong
Li, Pingdong
Gong, Yucui
Chen, Jieya
Wei, Lin
Zeng, Linghui
Zeng, Yingchun
Cheng, Andy SK.
author_sort Zhang, Guolong
collection PubMed
description OBJECTIVE: The aims of this study were to examine the symptom severity and interference among patients with lung cancer treated with PD-1 immunotherapy, explore whether those symptoms were clustered together, and identify factors associated with symptom clusters. METHODS: A cross-sectional study was conducted. Data were collected by demographic and clinical characteristic questionnaires and the M.D. Anderson Symptom Inventory Lung Cancer Module. Symptom clusters were identified using exploratory factor analysis, and stepwise linear regression was applied to analyze the factors affecting the symptom clusters. RESULTS: A total of 148 patients with lung cancer treated with PD-1 immunotherapy participated in this study. The overall symptom burdens of these patients were mainly at a mild level. The patient symptom clusters identified in this study were a general cluster, a treatment-related cluster, a pulmonary cluster, a gastrointestinal cluster, and a neural cluster. The patients’ Karnofsky performance status (KPS) score (β ​= ​−2.758, P ​< ​0.001) and having a history of chemotherapy (β ​= ​4.384, P ​= ​0.001) were significant predictors of the general cluster. Their KPS scores (β ​= ​−1.202, P ​< ​0.001) and having a history of chemotherapy (β ​= ​−1.957, P ​= ​0.001) were significant predictors of the pulmonary cluster. Their monthly income (β ​= ​−0.316, P ​= ​0.030) and KPS scores (β ​= ​−0.357, P ​= ​0.045) were significant predictors of the gastrointestinal cluster. Having a history of chemotherapy (β ​= ​1.868, P ​< ​0.001) was the predictor of the neural cluster. CONCLUSIONS: The symptom burdens of patients with lung cancer and treated with PD-1 immunotherapy were at a mild level and appeared to be clustered. In addition, because the symptoms that comprise a cluster are interrelated, the diagnosis and management of each symptom in a cluster should not be performed in isolation, and each symptom in a cluster should be treated either simultaneously or in an orderly manner.
format Online
Article
Text
id pubmed-9345784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93457842022-08-04 Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy Zhang, Guolong Weng, Huiwen Li, Yinghong Li, Pingdong Gong, Yucui Chen, Jieya Wei, Lin Zeng, Linghui Zeng, Yingchun Cheng, Andy SK. Asia Pac J Oncol Nurs Original Article OBJECTIVE: The aims of this study were to examine the symptom severity and interference among patients with lung cancer treated with PD-1 immunotherapy, explore whether those symptoms were clustered together, and identify factors associated with symptom clusters. METHODS: A cross-sectional study was conducted. Data were collected by demographic and clinical characteristic questionnaires and the M.D. Anderson Symptom Inventory Lung Cancer Module. Symptom clusters were identified using exploratory factor analysis, and stepwise linear regression was applied to analyze the factors affecting the symptom clusters. RESULTS: A total of 148 patients with lung cancer treated with PD-1 immunotherapy participated in this study. The overall symptom burdens of these patients were mainly at a mild level. The patient symptom clusters identified in this study were a general cluster, a treatment-related cluster, a pulmonary cluster, a gastrointestinal cluster, and a neural cluster. The patients’ Karnofsky performance status (KPS) score (β ​= ​−2.758, P ​< ​0.001) and having a history of chemotherapy (β ​= ​4.384, P ​= ​0.001) were significant predictors of the general cluster. Their KPS scores (β ​= ​−1.202, P ​< ​0.001) and having a history of chemotherapy (β ​= ​−1.957, P ​= ​0.001) were significant predictors of the pulmonary cluster. Their monthly income (β ​= ​−0.316, P ​= ​0.030) and KPS scores (β ​= ​−0.357, P ​= ​0.045) were significant predictors of the gastrointestinal cluster. Having a history of chemotherapy (β ​= ​1.868, P ​< ​0.001) was the predictor of the neural cluster. CONCLUSIONS: The symptom burdens of patients with lung cancer and treated with PD-1 immunotherapy were at a mild level and appeared to be clustered. In addition, because the symptoms that comprise a cluster are interrelated, the diagnosis and management of each symptom in a cluster should not be performed in isolation, and each symptom in a cluster should be treated either simultaneously or in an orderly manner. Elsevier 2022-06-10 /pmc/articles/PMC9345784/ /pubmed/35935261 http://dx.doi.org/10.1016/j.apjon.2022.100103 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Zhang, Guolong
Weng, Huiwen
Li, Yinghong
Li, Pingdong
Gong, Yucui
Chen, Jieya
Wei, Lin
Zeng, Linghui
Zeng, Yingchun
Cheng, Andy SK.
Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
title Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
title_full Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
title_fullStr Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
title_full_unstemmed Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
title_short Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
title_sort symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345784/
https://www.ncbi.nlm.nih.gov/pubmed/35935261
http://dx.doi.org/10.1016/j.apjon.2022.100103
work_keys_str_mv AT zhangguolong symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT wenghuiwen symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT liyinghong symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT lipingdong symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT gongyucui symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT chenjieya symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT weilin symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT zenglinghui symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT zengyingchun symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy
AT chengandysk symptomclustersandtheirpredictorsinpatientswithlungcancerandtreatedwithprogrammedcelldeathprotein1immunotherapy